UCB traded at 221.40 this Monday August 3rd, decreasing 1.50 or 0.67 percent since the previous trading session. Looking back, over the last four weeks, UCB lost 12.97 percent. Over the last 12 months, its price rose by 19.90 percent. Looking ahead, we forecast UCB to be priced at 217.91 by the end of this quarter and at 203.59 in one year, according to Trading Economics global macro models projections and analysts expectations.
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.